This appeal was based on the first-instance judgment made by the Beijing No. 1 Intermediate People's Court on June 2. On July 5, 2004, the Patent Reexamination Board issued Decision No. 6228 on the invalidation declaration request review, which held that Pfizer's patent for "Viagra" did not comply with relevant provisions of the patent law, and decided to declare its invention patent rights invalid. Subsequently, Pfizer began a nearly two-year-long patent dispute with the Patent Reexamination Board and took it to court. According to the first-instance judgment of this case, the Beijing No. 1 Intermediate People's Court determined that there were factual errors and legal misapplications in the No. 6228 decision made by the Patent Reexamination Board, thus revoking the invalidation declaration request review decision of the Patent Reexamination Board. This judgment was very unfavorable to the "Viagra Alliance." These companies had been waiting for the formal invalidation of the "Viagra" patent before pushing generic drugs onto the market. Wang Wei indicated that if the appeal succeeded, all enterprises in the "Viagra Alliance" would have the right to produce generic "Viagra." "We will strive for victory," said Wang Wei. Regarding the third-party appeal, Pfizer stated that it would not make any comments and remained confident in the patent for "Viagra," continuing to pursue legal procedures. Related thematic articles can be found at: Article source: http://www.gz-weige.cn